Evidence map›Paper›PMID 24305007›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2014

Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis.

Jun Shen, Jipei Liao, Maria A Guarnera, HongBin Fang, Ling Cai, Sanford A Stass, Feng Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  5. Pooled it
  6. MicroRNAs as ideal biomarkers for the diagnosis of lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  7. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  8. Pooled it
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Microbiota Biomarkers for Lung Cancer.Diagnostics (Basel, Switzerland) · 2021
    Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun Shen*Department of Pathology and †Division of Biostatistics, The University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
Jipei Liao
Maria A Guarnera
HongBin Fang
Ling Cai
Sanford A Stass
Feng Jiang

Funding

Non-invasive Biomarker Panels for Early Detection of Lung Squamous Cell CarcinomaR01CA161837 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI JIANG, FENG · 2011 to 2013
$998k
Early detection of lung cancer in VeteransI01CX000512 · VA · BALTIMORE VA MEDICAL CENTER · PI JIANG, FENG · 2012 to 2020
–
CSRD VA I01 CX000512NCI NIH HHS R01 CA161837NCI NIH HHS R01CA161837
6 · The paper itself

Abstract

introductionComputed tomography (CT) plays a central role in lung cancer diagnosis. However, CT has relatively low specificity, presenting a challenge in clinical settings. We previously identified 12 microRNAs (miRNAs) whose expressions in tumor tissues were associated with lung cancer.

methodsUsing quantitative reverse transcriptase polymerase chain reaction, we aimed to identify miRNA biomarkers in sputum that could complement CT for diagnosis of lung cancer.

resultsIn a training set consisting of 66 lung cancer patients and 68 cancer-free smokers, 10 of the 12 miRNAs were differentially expressed between the cases and controls (p ≤ 0.01). From the miRNAs, a logistic regression model was built on the basis of miR-31 and miR-210, both of which had the best prediction for lung cancer, producing an area under receiver operating characteristic curve of 0.83. Combined use of the two miRNAs yielded 65.2% sensitivity and 89.7% specificity, CT had 93.9% sensitivity and 83.8% specificity for lung cancer diagnosis. Notably, combined analysis of the miRNA biomarkers and CT produced a higher specificity than does CT used alone (91.2% versus 83.8%; p < 0.05). The diagnostic performance of the biomarkers was confirmed in a testing set comprising 64 lung cancer patients and 73 cancer-free smokers.

conclusionThe sputum miRNA biomarkers might be useful in improving CT for diagnosis of lung cancer, but further independent validation on an external and prospective cohort of patients is required.

Indexed as

AgedBiomarkers, TumorFemaleHumansLung NeoplasmsMaleMicroRNAsMiddle AgedReverse Transcriptase Polymerase Chain ReactionSensitivity and SpecificitySputumTomography, X-Ray ComputedBiomarkers, TumorMicroRNAs

Identifiers

PMID24305007
PMCPMC4967496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.